Meta-analysis finds benefit to bevacizumab triluridine/tipiracil colorectal cancer
Click Here to Manage Email Alerts
In a meta-analysis of triluridine/tipiracil (TAS-102) plus bevacizumab triluridine/tipiracil alone, there was a benefit to adding bevacizumab for patients with lateline colorectal cancer that is metastatic.
The meta-analysis looked at 29 studies 10,285 patients, of which several were randomized, many were phase 2 studies, and some were observational studies, said Howard S. Hochester, MD, an author on the study in an interview with Healio.
"In the end, after looking at reports of 10,000 patients, it seems that there is a benefit of adding bevacizumab to TAS-102. It gave a little bit higher response rate of 4% compared 2%, but mainly, the median progressionfree survival was almost twice as high," Hochester, associate director for clinical research and director of GI Oncology at Rutgers Cancer Institute, said.
There were no significant differences in the toxicity rates, he added.
Triluridine/tipiracil has been approved for lateline metastatic colorectal cancer for patients who have already had primary chemotherapy and targeted therapy drugs, Hochester said.
The question his team wanted to address in this meta-analysis was whether it's better to give triluridine/tipiracil with bevacizumab, an anti-VEGF antibody or by itself.
"In general, this would support the idea of giving bevacizumab with TAS-102 in lateline colon cancer," Hochester said.
Only one other study has looked at this direct comparison, Hochester said. The literature included in their meta-analysis from databases such as MEDLINE, Embase and Cochrane Library; the previous years of proceedings from ASCO, ESMO and AACR; registries such as Clinicaltrials.gov and UMIN; systematic review bibliographies; gray literature; and clinical guidelines through June 2021.
Collapse
Read more about
Click Here to Manage Email Alerts